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tau and inhibits tau aggregation in vitro and in vivo. Fur-
thermore, anle138b treatment effectively ameliorates dis-
ease symptoms, increases survival time and improves cog-
nition of tau transgenic PS19 mice. In addition, we found 
decreased synapse and neuron loss accompanied by a 
decreased gliosis in the hippocampus. Our results suggest 
that reducing tau aggregates with anle138b may represent 
an effective and promising approach for the treatment of 
human tauopathies.
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Introduction
The conversion of soluble tau monomers into insoluble 
fibrils is a key component in the pathogenesis of neuro-
degenerative tauopathies, including Alzheimer’s disease, 
frontotemporal dementia and parkinsonism linked to chro-
mosome 17, Pick’s disease, progressive supranuclear palsy, 
and corticobasal degeneration [30, 44]. In Alzheimer’s dis-
ease, tau pathology correlates with neuronal loss and clini-
cal symptoms [2, 10, 18]. In experimental mouse models, 
accumulation of aggregated tau is associated with memory 
deficits and neurodegeneration [6, 40, 41]. Inhibiting the 
aggregation of tau with small molecules reduced neurotox-
icity in vitro [29]. Together, these observations suggest that 
aggregated tau is not merely a neuropathological marker; 
tau aggregation rather represents a main target of a disease-
modifying therapy for tauopathies.
At present, no disease-modifying treatment for tauopa-
thies exists [25, 44]. Despite the identification of tau aggre-
gation inhibitors in vitro [4, 13, 38, 39, 48], only methyl-
ene blue was tested in a tau transgenic mouse model and 
Abstract Pathological tau aggregation leads to filamen-
tous tau inclusions and characterizes neurodegenerative 
tauopathies such as Alzheimer’s disease and frontotempo-
ral dementia and parkinsonism linked to chromosome 17. 
Tau aggregation coincides with clinical symptoms and is 
thought to mediate neurodegeneration. Transgenic mice 
overexpressing mutant human P301S tau exhibit many 
neuropathological features of human tauopathies including 
behavioral deficits and increased mortality. Here, we show 
that the di-phenyl-pyrazole anle138b binds to aggregated 
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clinical trials are underway. However, methylene blue has 
several targets [1, 16, 20, 36, 37]. Therefore, the thera-
peutic effects and reduction of tau aggregates may not be 
exclusively based on protein aggregation inhibition. Thus, 
it is not clear whether inhibition of tau aggregation is ben-
eficial in mouse models of tauopathy. Here, we test a new 
compound with high bioavailability and low toxicity [47] 
with regard to tau aggregation inhibition and therapeutic 
efficacy in a tau transgenic mouse model.
Previously, it has been shown that the di-phenyl-pyrazole 
anle138b [5-(1,3-benzodioxol-5-yl)-3-(3-bromophenyl)-
1H-pyrazole] acts as an oligomer modulator of α-synuclein 
and prion protein. Anle138b delays disease progression in 
mouse models of both prion disease and Parkinson’s dis-
ease by targeting pathological aggregates of α-synuclein 
and prion protein [47]. A characteristic of several aggrega-
tion inhibitors represents their ability to block the patholog-
ical aggregation of other proteins like Aβ and α-synuclein 
[34]. Based on this, we hypothesized that anle138b could 
also reduce pathological tau aggregates in vivo and delay 
disease progression in a mouse model of tauopathies.
We chose transgenic PS19 mice overexpressing mutant 
human tau (P301S) [50]. In humans, the P301S mutation 
causes familial frontotemporal dementia [12, 43]. This 
well-characterized mouse model displays the identified 
neuropathological hallmarks of human tauopathies, patho-
logical behavioral phenotypes, and increased mortality 
[11, 50]. We administered anle138b orally from weaning 
to terminal disease, and examined both pathogenesis and 
survival. Non-transgenic littermates (ntg) were likewise 




PS19 human tau transgenic mice [50] were obtained from 
The Jackson Laboratories (Stock number 8169, The Jack-
son Laboratory) and group housed separated by gender in 
individually ventilated cages (IVCs) under specified path-
ogen-free (SPF) conditions. Age- and sex-matched non-
transgenic littermates were used for all experiments and 
equal numbers of male and female mice were randomly 
assigned to the experimental groups. Mice had unlimited 
access to food and water, the light and dark cycle was 
12 h/12 h and the temperature was kept constant at 22 °C. 
The age of mice was 10 to 12 months for biochemical 
and immunohistochemical analysis. For cognitive perfor-
mance test, mice were 9 months of age. The compound 
anle138b was administered with drug-supplemented food 
pellets (2 g compound/kg food; Ssniff, Soest, Germany). 
The compound was added during the manufacturing pro-
cess of the food pellets as dry powder without a vehicle. 
Therefore, control mice were treated with non-supple-
mented food pellets. The treatment was initiated after 
weaning and lasted until the time of kill. Animals were 
monitored daily for clinical signs by trained animal care-
takers blinded to the study design and body weight was 
assessed monthly. The animals were killed, when they 
had reached the terminal stage of disease. From all ani-
mals, we collected one brain hemisphere, which was 
immediately frozen at −80 °C, for biochemical analysis 
and the other hemisphere after fixation in 4 % paraform-
aldehyde for histological analysis. The experimental pro-
cedures were in accordance with guidelines established 
by the DZNE and were approved by the government of 
North-Rhine-Westphalia.
Protein purification and aggregation
Tau isoform hTau46 (1N4R) was expressed from a 
pRK172 vector in BL21(DE3) E. coli cells. The cells 
were grown at 37 °C in LB medium containing 100 µg/
mL ampicillin. Protein expression was induced by addi-
tion of 1 mM isopropyl-1-thio-β-d-galactopyranoside. 
After 3 h of incubation cells were harvested by centrifuga-
tion, resuspended in 50 mM NaPi pH 7.0 containing 1 mM 
EGTA and 1 mM DTT, and lysed by boiling for 30 min. To 
remove cell debris, the lysate was centrifuged for 15 min 
at 14,600 rpm and 4 °C in a Th-641 rotor. The superna-
tant was filtered through a 45-µm filter and loaded onto 
a GE HiTrap SP HP column (5 mL). The bound protein 
was eluted with a salt gradient from 0 to 300 mM NaCl. 
Elution fractions containing hTau46 were pooled and 
loaded onto PD-10 desalting columns. hTau46 was eluted 
in 50 mM Tris pH 7.0 and the protein concentration was 
determined via a BCA assay. The eluate was collected in 
aliquots, frozen in liquid nitrogen and stored at −80 °C. 
For aggregation, frozen hTau46 was thawed at RT and 
incubated in 50 mM Tris pH 7.0 containing 0.02 % NaN3 
and 0.03 mg/ml heparin sodium salt (Sigma Aldrich, 
Switzerland) for 72 h at 37 °C under constant agitation 
(1000 rpm). Aggregated hTau46 was frozen in liquid nitro-
gen and stored at −80 °C. The monomeric and aggregated 
protein was thawed at RT directly before the fluorescence 
measurements.
Anle138b fluorescence measurements
All fluorescence measurements were performed with 
a spectrofluorometer (Horiba, Fluorolog3) at 300 nm 
excitation wavelength (power: 0.9 µW, front face geom-
etry) in combination with a home build stirring system, 
as described previously [47]. In brief, two solutions of 
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anle138b (250 nM) were prepared in buffer (containing 
0.0025 % DMSO). The first solution (S1) was obtained 
by adding 5 µl of a 10 mM anle138b solution in DMSO 
to 200 ml buffer (50 mM Tris buffer pH 7.0). To stabilize 
aggregated hTau46 the second solution (S2) was pre-
pared by adding additionally 0.02 % NaN3 and 0.03 mg/
mL heparin sodium salt (Sigma). Both solutions were 
stirred under ultra-sound for 10 min at about 30 °C. Two 
fused silica cells (Hellma, 10 × 4 mm, Typ 117.104F-
QS) were filled with solutions S1 and S2 and fluores-
cence spectra were recorded. Every 15 min monomeric 
(from a 22 µM stock solution) and aggregated (9.3 µM 
stock solution) hTau46 was added to cells S1 and S2, 
respectively. The volumes of added stock solution were 
adjusted to yield the concentrations given in (Fig. 1a). 
Fluorescence measurements were performed for both 
cells after each protein addition step. To correct for the 
small emission of tyrosine of the hTau46, the fluores-
cence spectra of two reference cells containing the same 
amount of monomeric and aggregated hTau46 as well 
as the same buffer solutions but no anle138b were sub-
tracted. All data have been smoothed via moving average 
over five points.
In vitro tau aggregation assay
The human tau isoform hTau46 (1N4R) was expressed 
in E. coli BL 21 (DE3) RIL and subsequently purified as 
described previously [3]. To prepare tau protein for confo-
cal single molecule measurements, it was labeled with fluo-
rescent dyes Alexa488-O-succinimidyl-ester or Alexa647-
O-succinimidyl-ester (Invitrogen, Darmstadt, Germany) as 
described. Fluorescently labeled tau was mixed as a tenfold 
stock solution in 50 mM tris buffer, pH 7.0. The stock solu-
tion was adjusted to a final ratio of tau-488 to tau-647 of 
approximately 1:1. The final concentration of labeled tau in 
the aggregation assay was between 10 and 20 nM in a total 
sample volume of 20 μl. Before each aggregation experi-
ment, preformed oligomers were removed by ultracentrifu-
gation, and the stock solution was scanned for pre-existing 
aggregates by SIFT. Only samples free of preformed aggre-
gates were used.
The tau aggregation assay was conducted with minor 
modifications as published previously for an α-synuclein 
aggregation assay [47]. In brief, experiments were per-
formed in 50 mM Tris buffer (pH 7.0) in a total volume 
of 20 μl in 384-well plates with a cover slide, bottom 
Fig. 1  Anle138b binds to 
aggregated tau and reduces tau 
aggregates in vitro. a Fluores-
cence spectrometry of anle138b 
(250 nM) excited at 300 nm 
with tau monomers (left panel) 
and pre-aggregated tau protein 
(right panel). Tau monomers 
did not change the fluorescence 
spectra of anle138b, whereas 
addition of pre-aggregated tau 
protein changed the fluores-
cence properties of anle138b 
and increased fluorescence at 
340 nm. b Exemplary SIFT 
measurement (SIFT scan-
ning for intensely fluorescent 
targets). c The formation of tau 
aggregates in vitro is signifi-
cantly inhibited by the applica-
tion of anle138b (p < 0.05, t 
test). d Correlation between 
tau anti-aggregative effect and 
compound brain concentra-
tion. Anle138b shows the best 
correlation of tau aggregation 
inhibition and bioavailability
622 Acta Neuropathol (2015) 130:619–631
1 3
(Greiner Bio-One, Germany). Plates were covered with 
adhesive film to obviate evaporation. Tau aggregation 
was monitored in presence of final concentrations of 1 % 
DMSO and 10 µM AlCl3. Compounds were diluted into 
the assay mixture from tenfold stock solutions contain-
ing 10 % DMSO (v/v), resulting in a final concentration 
of 1 % DMSO in all samples. Experiments were started by 
diluting the tenfold stock solution of fluorescently labeled 
Tau into a well, containing 1 % DMSO and 10 µM AlCl3 or 
1 % DMSO, 10 µM AlCl3 and 10 μM anle138b. Measure-
ments were started after an incubation period of 30 min. 
Aggregation was monitored at room temperature for at 
least 1 h in 5 independent samples for each experimental 
group by scanning for intensely fluorescent targets (SIFT) 
[8]. SIFT measurements were carried out on an Insight 
Reader (Evotec-Technologies) with dual-color excitation 
at 488 and 633 nm, using a 40 × 1.2 numerical aperture 
microscope objective (Olympus, Japan) and a pinhole 
diameter of 70 μm at Fluorescence Intensity Distribution 
Analysis (FIDA) setting. Excitation power was 200 μW at 
488 nm and 300 μW at 633 nm. Measurement time was 
10 s. Scanning parameters were set to 100 μm scan path 
length, 50 Hz beam scanner frequency, and 2000 μm posi-
tioning table movement. The fluorescence data were ana-
lyzed by SIFT analyze software (Evotec OAI, Germany) 
as described [19].
Pharmacokinetic analysis of brain concentrations 
of anle138b
Mice (C57BL6) were single housed and compounds were 
administrated in peanut butter. Animals were killed after 
4 h of administration. Brains were taken out and imme-
diately frozen in liquid nitrogen. Samples were stored at 
−80 °C.
The tissues were thawed at 4 °C prior to use. It was 
homogenized twice in 5 mL of acetonitrile at maximum 
speed for 3 min using a homogenizer (IKA ULTRA-TUR-
RAX Tube drive workstation, Germany). The homogenate 
was ultrasonicated at 30 °C for 5 min and centrifuged at 
5000×g for 10 min. An aliquot (100 µL of supernatant) was 
injected into HPLC system. Briefly, analytical high-per-
formance liquid chromatography (HPLC) was performed 
using a Waters HPLC system with a Waters 996 Photodiode 
Array Detector. All separations involved a mobile phase of 
0.1 % trifluoroacetic acid (TFA) (v/v) in water (solvent A) 
and 0.1 % TFA in acetonitrile (solvent B). HPLC was per-
formed using reversed-phase (RP) column Eurospher RP 
18, 100 Å, 5 µm, 250 × 4.6 mm at flow rates of 1 mL/min 
with a gradient of solvent B from 0 to 100 % in 50 min. 
The effluent was monitored for UV absorption at 260 nm. 
Samples were quantified using peak area ratio of com-
pounds to external standard.
Brain tissue extracts and immunoblot analysis
Brain tissue was weighed and homogenized in brain lysis 
buffer (50 mM Tris/HCl pH 7.4, 150 mM NaCl, 10 mM 
EDTA pH 8.0, 1 % (v/v) NP-40, 1 % (w/v) deoxycholate, 
1 µM okadaic acid, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 1 mM 4-(2-Aminoethyl)benzenesulfonyl fluoride 
(AEBSF), 20 mM sodium fluoride, 5 mM sodium vanadate, 
5 mM sodium pyrophosphate, protease inhibitor cocktail 
(Sigma Aldrich, Switzerland)) using the tissue homog-
enizer Precellys 24 (Peqlab, Erlangen, Germany). Brain 
homogenates were stored in aliquots at −80 °C.
Quantification of sarkosyl-insoluble tau protein was 
performed as described by Terwel et al. [45] with minor 
modifications. Briefly, brain homogenate was centri-
fuged at 15,0000×g for 30 min. The resulting pellet was 
resuspended in extraction buffer (10 mM Tris–HCl pH 
7.4, 1 mM EGTA, 0.8 M NaCl, 0.1 M PMSF, 10 % (w/v) 
sucrose) and centrifuged at 20,000×g for 20 min. The 
supernatant was adjusted to 1 % (w/v) sarkosyl and incu-
bated for 1 h at room temperature with constant agitation. 
After centrifugation at 150,000×g for 30 min, the pellet 
was resuspended in 50 mM Tris–HCl pH 7.4 (500 µL/g 
brain tissue). Sarkosyl-insoluble tau protein was detected 
with the tau antibodies HT7 (1:5000; ThermoScientific) 
and AT100 (1:1000; ThermoScientific). Insoluble tau was 
normalized relative to the tissue weight.
For quantification of total tau, brain homogenates were 
separated by SDS-Page on 10 % polyacrylamide (Appli-
chem, Darmstadt, Germany) gels and transferred to PVDF 
membranes (Immobilon-P, Millipore, USA). For immuno-
blotting, the membrane was blocked with Tropix I-Block 
(Applied Biosystems) and incubated with the primary anti-
body HT7 (1:5000; ThermoScientific) and E178 (1:5000; 
Abcam) at 4 °C overnight. After three washes in PBST, the 
membrane was incubated with a secondary antibody (goat 
anti-mouse-AP (1:10000); Cell Signaling). Tau protein 
was visualized with CDP-Star detection solution (Roche 
Applied Science, Germany). Immunoblots were quanti-
fied by a luminescence imaging system (Stella, Raytest, 
Germany) along with the AIDA software package (Ray-
test, Germany). The amount of total tau was normalized to 
GAPDH.
For quantification of phosphorylated tau, brain homoge-
nates were separated by SDS-Page on 10 % polyacrylamide 
(Applichem, Darmstadt, Germany) gels and transferred to 
PVDF membranes (Immobilon-FL, Millipore, USA). For 
immunoblotting, the membrane was blocked with Odys-
sey Blocking Buffer (TBS) (LI-COR) and incubated with 
the primary antibodies E178 (monoclonal Rabbit; 1:5000; 
Abcam), AT8 (monoclonal mouse; 1:1000; ThermoSci-
entific) and AT180 (monoclonal mouse; 1:1000; Thermo-
Scientific) at 4 °C overnight. After three washes in TBST, 
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the membrane was incubated with fluorescently labeled 
secondary antibodies (IRDye 680RD goat anti-rabbit; LI-
COR) and (IRDye 800CW goat anti-mouse; LI-COR). Tau 
protein was visualized by scanning the membranes with 
an Odyssey Classic Imager (LI-COR). Immunoblots were 
quantified with ImageJ software package 1.50b (National 
Institutes of Health, USA). The amount of phosphorylated 
tau was normalized to total tau in each lane.
Discontinuous sucrose gradient
Brain homogenates were adjusted to 1 % (w/v) sarkosyl 
and incubated for 2 h at 20 °C with constant agitation. After 
incubation, the homogenates were centrifuged at 5000×g 
for 5 min. The supernatant was layered onto a sucrose step 
gradient (10–50 % sucrose; 400 µL 10 % sucrose, 20–50 % 
sucrose 500 µL each) and centrifuged for 2 h at 200,000×g 
at 20 °C in a SW45Ti rotor (Beckman Coulter) using an 
Optima ultracentrifuge (Beckman Coulter). The fractions 
(500 µL) were collected from the bottom to the top. Sam-
ples were separated by SDS-Page on 8 % polyacrylamide 
(Applichem, Darmstadt, Germany) gels and detected with 
the tau antibody HT7 (1:5000; ThermoScientific). The 
amount of total tau loaded onto the sucrose gradient was 
normalized to GAPDH.
Histology and immunohistochemistry
Mice were transcardially perfused with cold PBS after 
being deeply anesthetized. The brains were removed and 
weighed. From all animals one brain hemisphere was fixed 
in 4 % paraformaldehyde for 24 h for histological exami-
nation. After fixation, the brain tissue was sectioned into 
50 µm tissue slices using a Leica VT1000S vibratome 
(Leica, Wetzlar, Germany) and immunohistochemistry was 
performed as described by Gogolla et al. [22] with minor 
modifications. Briefly, the sections were incubated with 
permeabilization solution (1 % Triton X-100 in PBS) for 
12 h under constant agitation. Subsequently, the slices were 
blocked with 20 % BSA in PBS buffer for 6 h. Then, the 
tissue sections were stained with the following primary 
antibodies in 3 % BSA/PBS overnight: tau protein (AT8, 
0.3 µg/mL; AT100, 1 µg/mL, ThermoScientific; MC1, 
1:500, a generous gift from Peter Davies), neuronal marker 
(NeuN, 1 µg/mL, Millipore; Nissl, 1:200, LifeTechnolo-
gies), synapses (anti-synaptophysin, 1:500, Millipore), 
microglia (Iba1, 1 µg/mL, Wako), astrocytic marker (anti-
GFAP, 0.3 µg/mL, LifeTechnologies), and autophagic 
marker (anti-LC3, 1:1000, Novus Biologicals; P62/
SQSTM1, 1:1000, Abcam). After three washes with 3 % 
BSA/PBS, the slices were incubated with a correspondent 
secondary antibody in 3 % BSA/PBS for 3 h (LifeTechnol-
ogies). Finally, the slices were mounted using fluorescence 
mounting medium (Dako, Hamburg, Germany) and images 
were acquired on an inverted Zeiss LSM700 confocal 
microscope and Zeiss AxioScan.Z1 (Zeiss, Germany). For 
Gallyas silver staining, brain tissue was fixed in 4 % para-
formaldehyde followed by paraffin embedding. Sections 
were silver impregnated following the Gallyas method to 
detect tau tangles. For quantitative analysis of tau pathol-
ogy with the tau stains AT8, MC1 and Gallyas, we quanti-
fied the positively stained area in matched brain sections. 
Quantification was done with the ZEN software package 
(Zeiss, Germany). For quantification of neuronal loss, the 
NeuN-stained area of the hippocampal CA3 region was 
quantified in matched brain sections. For each mouse, three 
sections per brain were quantified. The NeuN area was ana-
lyzed using imaging software ImageJ. Synaptic loss was 
analyzed by determining the thickness of stratum lucidum 
within the same hippocampal CA3 region used for NeuN 
quantification. Microglial and astrocytic cells per hip-
pocampal section were quantified by counting the number 
of Iba1-positive or GFAP-positive cell bodies, respectively. 
For each mouse, three sections per brain and two visual 
fields (each 500 µm × 500 µm) per section were quanti-
fied. Quantification was done with ImageJ 1.48a software 
(National Institutes of Health, USA).
Open‑field test and object–place recognition
Novelty recognition memory was tested in the context of an 
object–place recognition task. Only mice without obvious 
motor phenotype were tested in the object–place recogni-
tion task. Behavioral testing was performed as described by 
Bevins and Besheer [7] with minor modifications. Briefly, 
mice were handled for 1 min per day for 3 days. Then, mice 
were habituated to the testing environment and procedure 
for another 3 days. Therefore, mice were transferred to the 
testing room and given at least 1 h to acclimate. Mice were 
habituated to the arena (white 25 × 25 cm square plastic 
chambers) without stimuli for 15 min. The first habituation 
session was recorded for subsequent data analysis with an 
automated tracking system (Ethovision XT, Noldus Infor-
mation Technology) and analyzed as an open-field test. 
On the forth day (training session), mice were allowed to 
explore the arena that now contained two identical objects 
(small glass bottles) in defined locations of the arena for a 
period of 10 min. After a 1-h delay, the mice were presented 
with the same two objects and the test phase began. During 
testing, one object was in the exact same location as dur-
ing the training phase, whereas the other object was placed 
in a novel location. The mice were allowed to explore the 
objects for 5 min. The arena and objects were cleaned 
with 70 % ethanol between trials to remove olfactory cues. 
Behavior was scored as object exploration, whenever the 
animal‘s nose was in contact with the object or directed 
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towards the object (distance ≤2 cm). Discrimination ratios 
were calculated as following: exploration time object 1 or 
2/sum of exploration times object 1 and 2. Behavior was 
videotaped for offline analysis and an experienced observer 
quantified exploration times.
Statistical analysis
Quantifications and statistical analysis were carried out 
using GraphPad Prism. To determine statistically sig-
nificance t tests, two-way ANOVA tests, Mann–Whitney 
tests, and Log-Rank tests were carried out. The results of 
the significance tests are reported as follows: *p < 0.05; 
**p < 0.01; ***p < 0.001. All values are displayed as 
mean ± SEM if not otherwise stated.
Results
Reduced tau aggregation in vitro
First, we tested whether anle138b binds to aggregated tau 
protein in vitro. In a fluorescence spectroscopy assay, the 
fluorescence properties of anle138b at an excitation of 
300 nm were analyzed after addition of recombinant tau 
protein. Anle138b exhibits weak fluorescence intensity 
in aqueous buffer, which is unchanged after addition of 
monomeric tau protein (Fig. 1a). After addition of in vitro 
aggregated tau the fluorescence intensity of anle138b 
increased, indicating a structure-dependent binding of 
anle138b to aggregated tau protein (Fig. 1a). In a cell 
free in vitro tau aggregation assay with subsequent scan-
ning for intensely fluorescent targets (SIFT) analysis [8], 
we examined the effect of anle138b on tau aggregation 
(Fig. 1b). The tau aggregation assay is closely related to 
an assay that was used to study the effect of DPP com-
pounds on alpha-synuclein aggregation [47] and the effect 
of tau phosphorylation on oligomer formation [35]. Since 
Castillo-Carranza [14] recently hypothesized that tau oli-
gomers are the main toxic particle species in tauopathies, 
we analyzed the fluorescence data from the tau aggrega-
tion assay by cross-correlation (Fig. 1c) as cross-correla-
tion detects oligomeric protein aggregates with higher sen-
sitivity. We found that anle138b significantly suppressed 
tau oligomer formation (Fig. 1c). Next, we analyzed the 
tau anti-aggregative effect and the brain concentration of a 
couple of DPP compounds (Suppl. Fig. 1). Since anle138b 
offers the best correlation of in vitro tau aggregation inhi-
bition and bioavailability (Fig. 1d), we chose anle138b for 
administration in PS19 mice. Thus, our data indicate that 
anle138b binds to aggregated tau protein and inhibits the 
formation of potentially toxic oligomeric tau aggregate 
species in vitro.
Anle138b inhibits the formation of tau aggregates 
in vivo
Since the brain bioavailability of many compounds is low 
due to insufficient blood–brain barrier penetration, we 
determined whether anle138b supplemented in food pel-
lets effectively passes the blood–brain barrier. Treatment 
with anle138b-chow led to micromolar concentration of 
the compound in the brain (Suppl. Fig. 2). Since anle138b 
inhibited the formation of tau aggregates in vitro, we asked 
whether anle138b similarly affects tau aggregation in vivo. 
To determine the extent of tau pathology in the brains of 
10- to 12-month-old mice treated from weaning to terminal 
phase of disease, we used multiple immunohistochemical 
and tangle specific stains to address the histopathologi-
cal features of tau pathology (Fig. 2). First, we assessed 
the area of phosphorylated tau detected with the phospho-
rylation-specific tau antibody AT8 [21]. In ntg mice, no 
phosphorylated tau was detectable (Fig. 2a). In PS19 mice 
phosphorylated tau was detected in cortical areas like the 
hippocampus, entorhinal and piriform cortex. Anle138b 
reduced the AT8-positive tau deposits in PS19 mice when 
comparing to untreated mice (Fig. 2a). A quantitative anal-
ysis of AT8 staining revealed that anle138b-treated PS19 
mice had significantly less (~50 %) AT8-positive area than 
untreated PS19 mice (Fig. 2d). In addition, to asses the 
number of neurons in different brain regions, we counted 
the number of AT8-positive neurons in the hippocampus, 
somatosensory/auditory cortex, and piriform/entorhinal 
cortex (Suppl. Fig. 3). Whereas, in the hippocampus and 
somatosensory/auditory cortex the number of AT8-positive 
neurons was reduced in anle138b-treated PS19 mice, there 
was no change in the piriform/entorhinal cortex. To con-
firm that anle138b reduces tau pathology in PS19 mice, we 
stained brain sections with the conformation-specific tau 
antibody MC1 that detects misfolded tau [27]. Accordingly, 
the anle138b-treated group exhibited only 50 % MC1 reac-
tivity of the untreated ones (Fig. 2b, e). Finally, we assessed 
with the Gallyas silver staining method whether anle138b 
treatment influenced tau tangle formation (Fig. 2c). Indeed, 
anle138b reduced the formation of silver-positive tau tan-
gles in the cerebral cortex as well as in the brain stem by 
~60 % (Fig. 2f; Suppl. Fig. 4).
Subsequently, we examined the levels of total and insol-
uble tau in the brains of PS19 mice using multiple tau anti-
bodies. Similar levels of total tau observed in treated and 
untreated mice using the tau antibodies HT7 and E178 
exclude a treatment-induced suppression of tau expression 
(Fig. 3a, b). Quantification with phosphorylation-specific 
antibodies showed that the level of phosphorylated tau at 
the AT8 site (Ser202 + Thr205) is reduced, whereas the tau 
levels at the AT180 site (Thr231) are unaltered (Fig. 3c, d). 
To further evaluate, whether anle138b treatment affected 
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the level of aggregated insoluble tau in vivo, we measured 
the levels of sarkosyl-insoluble tau after ultracentrifuga-
tion. Non-transgenic mice exhibited no insoluble tau either 
probed with the HT7 or AT100 antibody (Fig. 3e). Admin-
istration of anle138b significantly reduced the amount of 
the sarkosyl-insoluble tau (HT7 and AT100) in brains of 
10- to 12-month-old PS19 mice compared to untreated 
mice (Fig. 3e, f). We next tested whether anle138b treat-
ment influenced the size distribution of aggregated tau 
protein in the brain of PS19 mice. Therefore, we sepa-
rated tau aggregates depending on their molecular weight 
in a sucrose gradient (containing 1 % sarkosyl) by ultra-
centrifugation (Fig. 3g). Soluble tau (composed mainly 
of 63 kDa tau) was detected in the 20 % sucrose fraction 
and was unchanged between treated and untreated mice 
(Fig. 3g, h). Lower to higher molecular weight aggregates 
(30–50 % sucrose) primarily contained insoluble 64 kDa 
tau (Fig. 3e). Anle138b altered the size distribution of tau 
aggregates and significantly reduced larger insoluble tau 
species in the 50 % sucrose fraction in relation to untreated 
animals (Fig. 3g, h). However, lower molecular weight 
tau aggregates (30–40 % sucrose) remained unchanged 
(Fig. 3g, h). Summarizing, the histological and biochemical 
data indicate that anle138b inhibits the formation of patho-
logical higher molecular weight tau aggregates in vivo.
To examine whether the difference in the levels of tau 
phosphorylation upon anle138b treatment was due to 
changed kinase or phosphatase activity, we analyzed the 
effect on the tau kinase GSK3 and the tau phosphatase 
PP2A (Suppl. Fig. 5). The phosphorylation of GSK3 
increased slightly but not significantly (Suppl. Fig. 5a), 
and neither the expression level of PP2A nor PP2A-activ-
ity was different upon anle138b incubation in vitro (Suppl. 
Fig. 5b, c). These results indicate that anle138b most prob-
ably does not exert its effect through changing kinase- or 
phosphatase-dependent tau phosphorylation status. Further 
Fig. 2  Anle138b treatment reduces tau pathology in PS19 mice. a 
AT8 stainings of non-transgenic (ntg), untreated and anle138b-treated 
PS19 mice of coronal brain sections (upper panel) and hippocam-
pal CA1 area (lower panel). b, c Immunohistochemical staining of 
brain sections with the conformation-specific tau antibody MC1 (b) 
and Gallyas silver staining (c) in treated and untreated PS19 mice. 
d–f Quantification of AT8, MC1 and silver-positive area in treated 
and untreated PS19 mice (n = 9 mice/group; 10–12 months). Aster-
isks indicate significant differences relative to untreated PS19 mice 
(*p < 0.05; **p < 0.01; t test). Scale bars 500 µm in low-power 
images and 50 µm in high-power images
626 Acta Neuropathol (2015) 130:619–631
1 3
Fig. 3  Anle138b reduces insoluble tau levels in PS19 mice a Immu-
noblots of brain homogenates of non-transgenic (ntg), untreated and 
anle138b-treated PS19 mice probed with HT7 and E178 antibody 
detecting total tau. b Densitometric analysis of immunoblots show-
ing the brain protein levels of total tau (HT7 and E178) in untreated 
and anle138b-treated PS19 mice. (n = 7 mice/group; 10-12 months). 
c Immunoblots of brain homogenates of ntg, untreated and anle138b-
treated PS19 mice probed with the phosphorylation-specific anti-
bodies (AT8 and AT180) and phosphorylation-independent antibody 
E178. d Densitometric analysis of immunoblots showing phosphoryl-
ated tau (AT8, AT180) in untreated and anle138b-treated PS19 mice. 
(n = 10–11 mice/group; 10–12 months). Immunoblots using the anti-
bodies HT7 and AT100 (e) and densitometric analysis (f) of sarkosyl-
insoluble aggregated tau protein in the brain of untreated PS19 trans-
genic mice in comparison to anle138b-treated animals. (n = 9–10 
mice/group; 10–12 months). Immunoblots of sucrose-gradient cen-
trifugation fractions from untreated and anle138b-treated mouse brain 
homogenates, to separate tau aggregates according to their molecu-
lar weight (g) and densitometric analysis (h). Anle138b-treated PS19 
mice showed a significant reduction of high molecular weight spe-
cies in the 50 % sucrose fraction in comparison to untreated animals 
(n = 7 mice/group; 10–12 months). Asterisks indicate significant dif-
ferences relative to untreated PS19 mice (*p < 0.05; t test)
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mechanisms for reduced tau pathology represent stimulated 
autophagy or increased protein degradation [16, 42]. There-
fore, we examined the autophagy markers P62/SQSTM1 
and LC3 in brains of 10- to 12-month-old PS19 mice as 
well as proteasomal tau degradation over time in anle138b-
treated neurons (Suppl. Fig. 5). After immunohistochemi-
cal staining, we found unchanged localization and inten-
sity for P62/SQSTM1 and LC3 in both anle138b-treated 
and untreated PS19 mice (Suppl. Fig. 6a, b). As expected, 
P62/SQSTM1 and AT100-positive tau inclusions co-local-
ized in PS19 mice (Suppl. Fig. 6a). For LC3, we detected 
unchanged immunoreactivity in brains of anle138b-
treated or untreated PS19 mice (Suppl. Fig. 6b). Immu-
noblots showed similar levels of P62/SQSTM1 and LC3 
in anle138b-treated and untreated mice (Suppl. Fig. 6c). 
Densitometric analysis revealed that both autophagy mark-
ers were unchanged in anle138b-treated PS19 mice (Suppl. 
Fig. 6d, e). In primary neurons, anle138b treatment has no 
effect on proteasomal tau degradation and tau ubiquitina-
tion (Suppl. Fig. 6f, g). Thus, our data indicate that the 
reduced levels of aggregated tau in brains of anle138b-
treated PS19 mice are related to other mechanisms than 
increased autophagy or enhanced proteasomal degradation.
Attenuated neuropathological impairments
In Alzheimer’s disease, tau pathology correlates with syn-
apse and neuron loss [23, 33]. PS19 mice recapitulate syn-
apse and neuron loss in the hippocampal CA3 region [50]. 
Therefore, we quantified the area of NeuN-positive neu-
rons in this brain region at 10–12 months of age. NeuN-
immunoreactivity was unchanged comparing anle138b-
treated with untreated ntg mice (Fig. 4a, b). In PS19 mice, 
anle138b treatment significantly ameliorated neuronal loss 
(Fig. 4a, b). Next, we analyzed synaptic density in the stra-
tum lucidum adjacent to the CA3 region, by immunohis-
tochemical quantification of the marker synaptophysin. 
Untreated and anle138b-treated ntg littermates exhibited 
unchanged synapse density. However, untreated PS19 mice 
lost 55 % of synapses in stratum lucidum that was amelio-
rated by anle138b (Fig. 4c, d).
In human tauopathies and PS19 mice, gliosis correlates 
with the distribution of tau pathology [5, 26, 28, 46, 50]. 
Therefore, we analyzed micro- and astrogliosis in brains of 
untreated and anle138b-treated mice. Anle138b treatment 
significantly reduced the number of microglia in the hip-
pocampus compared with untreated PS19 mice (Fig. 4e, 
f). We also found that anle138b diminished GFAP stain-
ing in the hippocampus and reduced the number of acti-
vated astrocytes in PS19 mice compared with untreated 
animals (Fig. 4g, h). In ntg mice, the densities of both cell 
types were unaltered after anle138b treatment (Fig. 4g, h). 
Thus, anle138b treatment attenuated neuron and synapse 
loss in CA3 and stratum lucidum of the hippocampus. 
Moreover, neuroinflammation was less pronounced upon 
anle138b treatment, reflected by both reduced micro- and 
astrogliosis.
Prolonged survival and improved cognition
The high bioavailability of anle138b (Suppl. Fig. 2) 
allowed treating mice with the drug provided in food pel-
lets. This convenient way of drug application further ena-
bled us to treat mice for a time-period up to 17 months. 
Non-transgenic mice tolerated such a long treatment 
very well, since they did not show any change in survival 
compared to untreated mice (Fig. 5a). Like FTDP-17 
patients that carry a P301S tau mutation [12, 32], PS19 
mice showed accelerated mortality and 80 % of the mice 
died within 12 months (Fig. 5a). We tested the effect of 
anle138b on survival and recognition memory in PS19 ani-
mals. By 12 months of age, the absolute survival rate of 
anle138b-treated PS19 mice was 2.9 times higher than for 
untreated animals (p < 0.01; survival rates: untreated 16 %; 
anle138b 46 %; Fig. 5). Moreover, anle138b significantly 
prolonged the mean survival time of PS19 mice by almost 
6 weeks (Fig. 5a; Anle138b: 362 ± 12 days vs. untreated: 
321 ± 10 days; n = 37 mice/group; p < 0.05 t test). In addi-
tion, the rate of decline for mouse weight after onset of dis-
ease was significantly higher in untreated PS19 compared 
to anle138b-treated PS19 mice (Suppl. Fig. 7). Anle138b 
had no influence on survival of ntg animals (Fig. 5a). Thus, 
PS19 mice treated with anle138b showed an increased 
12 months absolute survival rate and a prolonged mean sur-
vival time.
Finally, since PS19 mice show deficits in spatial learning 
and memory [11], we addressed whether anle138b treat-
ment improved cognition. We carried out an object–place 
recognition task at 9 months of age and compared untreated 
and anle138b-treated animals (Fig. 5b). Ntg mice showed 
the expected increased exploration of an object in a novel 
location relative to an identical object in a known loca-
tion, indicating that animals had successfully memorized 
object–place relationships in this task. In untreated PS19 
animals, in contrast, exploration times of the object in the 
novel location did not differ significantly from those of the 
object in the known location, which is consistent with the 
notion of learning and memory impairments in PS19 mice 
[11]. Anle138b-treated PS19 animals, however, showed 
discrimination ratios that were restored to the levels of ntg 
mice, indicating that anle138b improved cognitive function 
in PS19 mutants. An Open-field test showed that this effect 
was not based on a motor deficit, since both groups trave-
led similar distances (Fig. 5c). Anle138b did not influence 
behavioral measures in ntg mice in any obvious manner, 
excluding a cognitive enhancer effect of the compound. 
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Together, these data indicate that anle138b treatment was 
sufficient to prevent the development of cognitive impair-
ments in PS19 mice.
Discussion
We found that anle138b inhibits the formation of pathologi-
cal tau aggregates in vitro and in vivo and thereby improves 
cognition, neuropathology and survival in a mouse model 
of tauopathies. Beyond that, anle138b represents a novel 
compound that significantly attenuates all features of 
human tauopathies recapitulated in the PS19 mouse model, 
such as cognitive decline, neuropathology, and accelerated 
mortality [11, 50]. Remarkably, anle138b preserves learn-
ing and memory at a time, when untreated mice become 
terminally ill, which points to a longer disease-free survival 
accompanied with unimpaired cognition. Thus, our find-
ings corroborate the concept that pathological tau aggrega-
tion plays a critical role in the pathogenesis of tauopathies 
[44] and pharmacological inhibition thereof represents a 
valid therapeutic target for a disease-modifying treatment 
of tauopathies.
The tau aggregation inhibitor methylene blue has been 
tested in tau transgenic mice as well [24, 48]. Methylene 
blue has multiple protein and molecular targets in vivo 
[1, 16, 20, 36, 37], so that the observed effects may not 
be exclusively based on the prevention of tau aggregation 
Fig. 4  Anle138b treatment ameliorates neuropathology of PS19 
mice NeuN staining (a) and quantification (b) of the hippocampal 
CA3 region of ntg, untreated and anle138b-treated PS19 mice. Stain-
ing with the synaptic marker synaptophysin in the stratum lucidum 
(c) and quantification (d) of ntg, untreated and anle138b-treated 
PS19 mice. Microglia Iba1 and astrocyte GFAP staining (e, g) and 
quantification (f, h) of ntg and PS19 mice treated and untreated with 
anle138b. a–h (n = 8–9 PS19 mice/group; n = 4–5 ntg mice/group; 
10–12 months). Scale bars 25 µm. Asterisks indicate significant dif-
ferences relative to untreated PS19 mice (*p < 0.05; **p < 0.01; 
***p < 0.001; two-way ANOVA with Bonferroni’s multiple-compar-
isons test)
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[31]. However, anle138b seems to primarily act by 
directly targeting formation of pathological tau aggre-
gates rather than by secondary off-target effects, since 
we found unchanged tau expression, tau ubiquitination 
and autophagy after administration of anle138b. With 
regard to the mode of action of anle138b, we showed 
that anle138b binds specifically to pre-aggregated tau 
and reduces the amount of oligomeric tau species at the 
molecular level in vitro. Upon anle138b treatment in 
PS19 mice, we detected reduced tau pathology in brain 
slices using histological stainings for phosphorylated and 
tangle tau. Biochemically, we found a reduced amount of 
large tau aggregate species without increasing the level 
of smaller tau aggregates in anle138b-treated PS19 mice. 
These results support the hypothesis that higher molec-
ular weight aggregates and tangles are neurotoxic and 
suggest that the therapeutic effect of anle138b in PS19 
mice is based on inhibiting the pathological aggrega-
tion process. In addition, there was neither an immune 
modulatory effect nor an obvious effect on cognition in 
ntg mice. Taken together, our data indicate that inhibition 
of tau aggregation is beneficial in vivo. Although further 
studies have to confirm the efficacy of anle138b before 
translation into human patients, we provide proof-of-
principle that pharmacological inhibition of pathological 
tau aggregation represents a feasible treatment option for 
tauopathies.
In addition to tau aggregation inhibition, anle138b 
has been previously shown to inhibit prion protein and 
α-synuclein aggregation [47]. These results point at a bind-
ing of anle138b to a common feature immanent of all three 
proteins.
Since tau pathology is associated with clinical symp-
toms in tauopathies [2, 10, 18], tau-directed therapies 
have moved into the focus of recent Alzheimer’s disease 
research [17]. Recently, potential tau-directed therapeutic 
approaches involved immunotherapy [9, 15, 49], or micro-
tubule-stabilizing drugs [11, 51], or enhanced autophagy 
[16, 42]. Most of these studies successfully reduced tau 
pathology and improved behavior. However, none of these 
studies aimed at inhibiting the tau aggregation at the molec-
ular level. Here, we present a tau aggregation inhibitor that 
ameliorates neuropathology and improves behavior. Nota-
bly, treatment up to 17 months in non-transgenic mice was 
well tolerated promising a high long-term therapy poten-
tial. Moreover, anle138b represents the first small molecule 
that significantly extended the mean survival time of tau 
transgenic mice.
Since none of the published tau-directed treatment strat-
egies, including our study, were sufficient to cure the dis-
ease in tau transgenic mice, we suggest that future treat-
ment strategies should be diversified to aim at various tau 
targets. It seems plausible that a combination of various 
therapeutic approaches like blocking the spread of tau 
pathology, stabilizing microtubules, enhancing autophagy, 
or inhibiting tau aggregation would be more effective.
In conclusion, inhibiting tau aggregation by small mol-
ecules represents a promising approach for the treatment of 
human tauopathies, where anle138b might serve as a new 
lead for developing a disease-modifying therapy.
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Fig. 5  Effect of anle138b treatment on survival and behavior in 
PS19 transgenic mice a Kaplan–Meier plots of PS19 transgenic and 
ntg mice. Anle138b treatment significantly prolonged survival time 
of PS19 mice (**p < 0.01; n = 37 mice/group; Log-Rank test) and 
attenuated 12-month survival rate compared with untreated PS19 lit-
termates (p < 0.01, Log-Rank test). b Learning and memory were 
analyzed at 9 months of age using an object–place recognition task. 
Gray line indicates chance level. Untreated PS19 mice did not show 
significantly higher exploration of the object in the novel location 
relative to the object in the known location (discrimination ratio n.s.), 
which is consistent with memory impairments. In contrast, Anle138b-
treated PS19 mice spent significantly more time exploring the object 
in the novel location, indicating that treatment restored learning and 
memory in PS19 mice (**p < 0.01; ***p < 0.001; n = 19–24 mice/
group; Significantly different from a hypothetical 0.50, one-sample 
t test). c Total distance traveled in the open-field test was similar 
in untreated and anle138b-treated mice independent of the geno-
type, indicating that motor behavior was unaffected in these animals 
(n = 19–24 mice/group)
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